NO20054238L - Inhibitorer av antigenpresentasjon ved MHC klasse II-molekyler og fremgangsmate for anvendelse av disse - Google Patents

Inhibitorer av antigenpresentasjon ved MHC klasse II-molekyler og fremgangsmate for anvendelse av disse

Info

Publication number
NO20054238L
NO20054238L NO20054238A NO20054238A NO20054238L NO 20054238 L NO20054238 L NO 20054238L NO 20054238 A NO20054238 A NO 20054238A NO 20054238 A NO20054238 A NO 20054238A NO 20054238 L NO20054238 L NO 20054238L
Authority
NO
Norway
Prior art keywords
methods
inhibitors
molecules
mhc class
antigen presentation
Prior art date
Application number
NO20054238A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054238D0 (no
Inventor
Gary L Olson
Charles Michael Cook
Christopher R Self
Original Assignee
Provid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provid Pharmaceuticals Inc filed Critical Provid Pharmaceuticals Inc
Publication of NO20054238D0 publication Critical patent/NO20054238D0/no
Publication of NO20054238L publication Critical patent/NO20054238L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
NO20054238A 2003-02-14 2005-09-13 Inhibitorer av antigenpresentasjon ved MHC klasse II-molekyler og fremgangsmate for anvendelse av disse NO20054238L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44794903P 2003-02-14 2003-02-14
PCT/US2004/004389 WO2004073625A2 (fr) 2003-02-14 2004-02-13 Inhibiteurs de la presentation d'antigenes par des molecules mhc classe i et methodes d'utilisation

Publications (2)

Publication Number Publication Date
NO20054238D0 NO20054238D0 (no) 2005-09-13
NO20054238L true NO20054238L (no) 2005-11-11

Family

ID=32908515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054238A NO20054238L (no) 2003-02-14 2005-09-13 Inhibitorer av antigenpresentasjon ved MHC klasse II-molekyler og fremgangsmate for anvendelse av disse

Country Status (11)

Country Link
US (3) US7439231B2 (fr)
EP (1) EP1605963B1 (fr)
AT (1) ATE533500T1 (fr)
AU (1) AU2004212954B2 (fr)
CA (1) CA2516080C (fr)
DK (1) DK1605963T3 (fr)
NO (1) NO20054238L (fr)
NZ (1) NZ542256A (fr)
PL (1) PL211458B1 (fr)
RU (1) RU2333219C2 (fr)
WO (1) WO2004073625A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211458B1 (pl) * 2003-02-14 2012-05-31 Provid Pharmaceuticals Związki, kompozycja farmaceutyczna zawierająca je oraz zastosowanie związków
US20100183658A1 (en) * 2007-03-30 2010-07-22 The Brigham And Women's Hospital, Inc. Novel Compounds for Enhancing MHC Class II Therapies
EP2229399A1 (fr) * 2007-12-03 2010-09-22 Provid Pharmaceuticals, Inc. Inhibiteurs de la présentation d'antigène par des molécules de classe ii du cmh et leurs procédés d'utilisation
EP2655395B1 (fr) 2010-12-23 2018-03-07 Universiteit Gent Procédé de réticulation de peptides
CN114615976A (zh) 2019-08-07 2022-06-10 人福医药美国公司 κ阿片受体肽酰胺激动剂
US12616732B2 (en) 2020-06-25 2026-05-05 Yichang Humanwell Pharmaceuticals Co., Ltd. Peptides for treatment of medical disorders
WO2021262173A1 (fr) 2020-06-25 2021-12-30 Humanwell Pharmaceutical US Peptides pour le traitement de troubles médicaux
WO2022197499A1 (fr) * 2021-03-19 2022-09-22 Provid Pharmaceuticals Inc. Inhibiteurs de présentation d'antigène par des molécules hla-drb1*15:01 de cmh de classe ii présentant une stabilité métabolique améliorée
US12545716B2 (en) 2021-07-19 2026-02-10 Immunome, Inc. Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US6077509A (en) 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
DE4340111A1 (de) * 1993-11-22 1995-05-24 Schering Ag Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
DE4342846A1 (de) * 1993-12-10 1995-06-14 Schering Ag Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
US5585980A (en) * 1994-06-09 1996-12-17 International Business Machines Corporation Low friction device for an actuator arm of a disk drive
US5559114A (en) * 1994-12-16 1996-09-24 Exley; Ray W. Treatment of autoimmune disease using 2-amino purine derivatives
US5874531A (en) 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5624902A (en) * 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
JPH11510792A (ja) * 1995-06-29 1999-09-21 トーマス ジェファーソン ユニバーシティー 免疫応答を阻害するｃｄ４−誘導ペプチド
US5859980A (en) * 1996-02-08 1999-01-12 Advanced Micro Devices, Inc. Network interface having adaptive transmit start point for each packet to avoid transmit underflow
GB9620819D0 (en) * 1996-10-05 1996-11-20 Zeneca Ltd Chemical compounds
FR2753707B1 (fr) * 1996-09-23 1998-12-11 Complexes nucleopeptidiques, compositions cosmetologiques et pharmaceutiques les contenant et utilisations
GB9621836D0 (en) * 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9624562D0 (en) * 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
US6891046B2 (en) 2000-04-26 2005-05-10 Smith, Iii Amos B. Solution and solid phase synthesis of pyrrolinones and polypyrrolinones
MXPA04009228A (es) 2002-03-22 2005-08-16 Gpc Biotech Ag Compuestos inmunosupresores, metodos y usos relacionados con los mismos.
PL211458B1 (pl) * 2003-02-14 2012-05-31 Provid Pharmaceuticals Związki, kompozycja farmaceutyczna zawierająca je oraz zastosowanie związków

Also Published As

Publication number Publication date
AU2004212954A1 (en) 2004-09-02
WO2004073625A2 (fr) 2004-09-02
EP1605963A4 (fr) 2007-02-14
AU2004212954B2 (en) 2008-07-17
EP1605963B1 (fr) 2011-11-16
PL378195A1 (pl) 2006-03-06
NO20054238D0 (no) 2005-09-13
PL211458B1 (pl) 2012-05-31
US20120252734A1 (en) 2012-10-04
RU2333219C2 (ru) 2008-09-10
WO2004073625A3 (fr) 2005-01-20
US8598312B2 (en) 2013-12-03
ATE533500T1 (de) 2011-12-15
RU2005128549A (ru) 2006-02-10
CA2516080A1 (fr) 2004-09-02
NZ542256A (en) 2009-05-31
DK1605963T3 (da) 2012-02-06
US8222215B2 (en) 2012-07-17
US20040162242A1 (en) 2004-08-19
CA2516080C (fr) 2021-11-02
US7439231B2 (en) 2008-10-21
EP1605963A2 (fr) 2005-12-21
US20090111755A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
MY161991A (en) Proteasome inhibitors
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201000424A1 (ru) Антитела к il-23
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
IS3013B (is) Meltikornatálmar og aðferðir til að nota þá
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20062767L (no) Immunoglobuliner
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
TW200510416A (en) P38 inhibitors and methods of use thereof
NO20064852L (no) Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
DE602005020611D1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
WO2005019258A3 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
EA200800763A1 (ru) Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
MX2007004841A (es) Triazoles utiles como inhibidores de proteinas cinasas.
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application